StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT - Free Report) in a research report released on Monday morning. The brokerage issued a sell rating on the biotechnology company's stock.
Separately, Alliance Global Partners assumed coverage on vTv Therapeutics in a research report on Monday, December 9th. They set a "buy" rating and a $35.00 price objective on the stock.
Check Out Our Latest Stock Analysis on VTVT
vTv Therapeutics Trading Down 2.8 %
vTv Therapeutics stock traded down $0.48 during trading on Monday, reaching $16.63. The company had a trading volume of 40,414 shares, compared to its average volume of 20,892. The firm's 50-day simple moving average is $16.29 and its 200 day simple moving average is $15.38. vTv Therapeutics has a 52 week low of $12.12 and a 52 week high of $30.99. The firm has a market capitalization of $53.03 million, a price-to-earnings ratio of -3.67 and a beta of 1.07.
Institutional Trading of vTv Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of VTVT. Geode Capital Management LLC boosted its holdings in vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock worth $158,000 after buying an additional 1,327 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of vTv Therapeutics in the fourth quarter valued at about $25,000. Finally, FMR LLC bought a new position in shares of vTv Therapeutics in the third quarter worth about $2,402,000. 17.51% of the stock is currently owned by institutional investors.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Further Reading
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
